Sterling Pharma Solutions

Name

Sterling Pharma Solutions

Legal name

Sterling Pharma Solutions

Website

https://sterlingpharmasolutions.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Contract API manufacturing
• Small molecule CDMO
• Antibody-drug conjugate manufacturing
• Oncology API development
• High-potency API manufacturing

Headquarters

HQ city

Cramlington

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Core offering

Sterling Pharma Solutions is a UK-based pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides small molecule API development and manufacturing services, high-potency API production, and antibody-drug conjugate (ADC) manufacturing for the global pharmaceutical industry. The company supports both early-stage and commercial-scale manufacturing and has expanded its complex process chemistry capabilities through the October 2023 acquisition of NewChem Technologies Ltd.

Product overview

Sterling Pharma Solutions operates as a pharmaceutical contract development and manufacturing organization (CDMO) providing small molecule and high-potency API manufacturing services. The company's portfolio includes complex process chemistry capabilities (enhanced through the October 2023 acquisition of NewChem Technologies Ltd.) and ADC manufacturing services for the oncology sector. The company positions itself within the broader contract research and manufacturing services (CRAMS) market.

Differentiator

Problem solved

Functional benefit

Products and services

• High-Potency API Manufacturing Contract manufacturing services for antibody-drug conjugates (ADCs) and oncology APIs, supporting both early-stage and commercial-scale manufacturing for pharmaceutical customers.
• Small Molecule API Development and Manufacturing End-to-end contract research and manufacturing services for small molecule active pharmaceutical ingredients, offered to the global pharmaceutical industry.
• Complex Process Chemistry Services Specialized process chemistry services for complex pharmaceutical molecules, provided through the acquired NewChem Technologies Ltd. business unit within Sterling Pharma Solutions.
• Continuous Manufacturing Services Continuous manufacturing technology applied to API production, capable of reducing operating costs by up to 50% and decreasing manufacturing cycle times by 80%.

Quantifiable outcome

• Continuous manufacturing can reduce operating costs by up to 50% and decrease manufacturing cycle times by 80%

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered flagship and core.

• SoligenixflagshipStrategic or Co-development Partner · 1 January 2024Sterling Pharma Solutions has a partnership with Soligenix for oncology API development. This collaboration represents Sterling's commitment to specialized capabilities in cancer therapeutic manufacturing within the pharmaceutical contract services sector.
• NewChem Technologies Ltd.coreStrategic or Co-development Partner · 1 October 2023Sterling Pharma Solutions acquired NewChem Technologies Ltd. in October 2023. This acquisition exemplifies strategic consolidation trends in the CRAMS sector, strengthening Sterling's capabilities in complex process chemistry and expanding its service offerings for pharmaceutical manufacturing.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Almac Group: UK/Northern Ireland-based CDMO offering API development, manufacturing, and pharmaceutical services. Directly comparable as a UK-headquartered, privately-held CDMO with similar scale and a comparable mix of API and finished dosage form services.
• Cambrex: US-headquartered CDMO specializing in small molecule API development and manufacturing. Directly competes with Sterling in the small-molecule CDMO space with comparable service offerings and customer base.
• Hovione: Portugal-based CDMO focused on complex API manufacturing, including highly potent and particle engineering. A direct peer given overlapping capabilities in complex chemistry, high-potency APIs, and contract manufacturing services.
• Recipharm: European CDMO offering development and manufacturing services for small molecule APIs and finished dosage forms. Comparable as a mid-to-large privately-held European CDMO with similar service breadth.
• Aenova Group: European CDMO providing solid dosage form development, manufacturing, and packaging services. Comparable as a European-based contract manufacturer serving pharma developers across multiple dosage forms.
• Curia (formerly AMRI): Global CDMO offering API development and manufacturing, drug product services, and biologics. A direct competitor in small molecule API manufacturing and contract services for pharmaceutical developers.
• Seqens: France-based integrated pharmaceutical and specialty chemicals company offering API manufacturing and custom synthesis. Comparable as a European-headquartered CDMO with similar small molecule and complex chemistry focus.

Broad incumbents

• WuXi STA (WuXi AppTec): Large global CDMO with extensive small molecule API and drug product capabilities. A broad incumbent in the same market space, though with significantly larger scale and geographic reach.
• Lonza Pharma & Biotech: Swiss-based global CDMO offering API and biologics manufacturing services. A broad incumbent that competes with Sterling across multiple service lines, particularly in API manufacturing for pharma developers.

Emerging players

• Quotient Sciences: UK-based CDMO offering drug development, formulation, and clinical manufacturing services. Comparable as a UK-headquartered CDMO focused on early-stage development and small molecule services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/sterling_pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sterling Pharma Solutions